GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InspireMD Inc (FRA:II2) » Definitions » EV-to-FCF

InspireMD (FRA:II2) EV-to-FCF : -1.09 (As of May. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is InspireMD EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, InspireMD's Enterprise Value is €17.02 Mil. InspireMD's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-15.55 Mil. Therefore, InspireMD's EV-to-FCF for today is -1.09.

The historical rank and industry rank for InspireMD's EV-to-FCF or its related term are showing as below:

FRA:II2' s EV-to-FCF Range Over the Past 10 Years
Min: -5.33   Med: 0.28   Max: 1.41
Current: -1.1

During the past 13 years, the highest EV-to-FCF of InspireMD was 1.41. The lowest was -5.33. And the median was 0.28.

FRA:II2's EV-to-FCF is ranked worse than
100% of 363 companies
in the Medical Devices & Instruments industry
Industry Median: 27.85 vs FRA:II2: -1.10

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), InspireMD's stock price is €2.22. InspireMD's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.977. Therefore, InspireMD's PE Ratio for today is At Loss.


InspireMD EV-to-FCF Historical Data

The historical data trend for InspireMD's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InspireMD EV-to-FCF Chart

InspireMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 -0.61 0.57 0.56 -1.43

InspireMD Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.12 -0.45 -1.82 -1.43

Competitive Comparison of InspireMD's EV-to-FCF

For the Medical Devices subindustry, InspireMD's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InspireMD's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where InspireMD's EV-to-FCF falls into.



InspireMD EV-to-FCF Calculation

InspireMD's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=17.019/-15.551
=-1.09

InspireMD's current Enterprise Value is €17.02 Mil.
InspireMD's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-15.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InspireMD  (FRA:II2) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

InspireMD's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.22/-0.977
=At Loss

InspireMD's share price for today is €2.22.
InspireMD's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.977.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


InspireMD EV-to-FCF Related Terms

Thank you for viewing the detailed overview of InspireMD's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


InspireMD (FRA:II2) Business Description

Traded in Other Exchanges
Address
4 Menorat Hamaor Street, Tel Aviv, ISR, 6744832
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries.

InspireMD (FRA:II2) Headlines

No Headlines